| Name | Company | P/L % | MPV |
|
|---|---|---|---|---|
| Lord Glendonbrook |
|
Stryker / NYQ:SYK | 363.02% | £324,115.53 |
| Lord Glendonbrook |
|
Abbott Laboratories / NYQ:ABT | 271.48% | £260,038.41 |
| Lord Sassoon |
|
Abbott Laboratories / NYQ:ABT | 185.29% | £199,702.12 |
| Lord Grabiner |
|
Boston Scientific / NYQ:BSX | 138.22% | £166,757.37** |
| Baroness Noakes |
|
Smith & Nephew / NYQ:SNN | 48.14% | £103,696.82 |
| Lord Glendonbrook |
|
Smith & Nephew / NYQ:SNN | 37.49% | £96,244.01 |
| Lord Mance |
|
Stryker / NYQ:SYK | 16.88% | £81,818.54 |
| Lord Glendonbrook |
|
Medtronic / NYQ:MDT | 10.66% | £77,463.33** |
| Lord Howard of Rising |
|
Ekf Diagnostics / LSE:EKF.L | -0.04% | £69,971.45 |
| Lord Londesborough |
|
Abbott Laboratories / NYQ:ABT | -13.75% | £60,376.77 |
| Lord Sassoon |
|
Medtronic / NYQ:MDT | -18.73% | £56,891.94 |
| Lord Glendonbrook |
|
Align Technology / NMS:ALGN | -35.24% | £45,331.87 |
| Lord Kakkar | Cyte / NMS:CTKB | -55.35% | £31,251.50** | |
| Lord Browne of Madingley | Allurion / NYQ:ALUR | -77.64% | £15,649.55 |